Alafair Biosciences, Inc. announced that surgeons have implanted over 12,000 units of its flagship product, VersaWrap®, in patients since commercial launch.
| AUSTIN, Texas, Nov. 21, 2023 /PRNewswire/ -- Alafair Biosciences, Inc., a commercial-stage medical device company, announced that surgeons have implanted over 12,000 units of its flagship product, VersaWrap®, in patients since commercial launch. This milestone reflects expanding surgeon adoption and clinical need for Alafair’s innovative technology. VersaWrap is the only class II medical device intended for use on tendon, ligament, skeletal muscle, and peripheral nerve, including on nerve root in spine procedures.
VersaWrap is an ultrathin, sutureless, bioresorbable hydrogel implant that forms a gelatinous layer around target tissues, facilitating gliding during healing and reducing postoperative tethering. VersaWrap may be implanted as a sheet or as a gel (via syringe). VersaWrap is primarily applied by plastic, orthopedic, hand, foot & ankle, and spine surgeons in a wide variety of procedures. “Following any surgery, scar tissue can cause post operative challenges, including nerve pain,” stated Dr. Anthony Echo, plastic surgeon at Houston Methodist. “In patients where I’ve applied VersaWrap, they report less pain, greater mobility, and a quicker return to normal routines.” “We are delighted to see the benefits of VersaWrap reaching a greater number of patients across multiple markets,” said John Joyoprayitno, Alafair President & Chief Executive Officer. “Alafair’s strong sales momentum is driven by our mission to improve surgeon experience and patient outcomes in all surgical applications. Patient care is at the forefront of everything we do.” About Alafair Biosciences, Inc. (www.alafairbiosciences.com)
SOURCE Alafair Biosciences, Inc. |
View original content to download multimedia:
